Table 1.
Descriptive statistics among groups, N=105.
| Variable | Normal n=17 | Overweight n=28 | Obese Class I n=30 | Obese Class II n=16 | Obese Class III n=13 | P-value |
|---|---|---|---|---|---|---|
|
| ||||||
| Age (mean, SD) | 57±14.5 | 61.6±8.7 | 58.7±10.5 | 60.3±9.7 | 59±10.8 | 0.703 |
| Body mass index (mean, SD) | 22.5±1.9 | 27.6±1.4 | 32.4±1.5 | 36.4±1.3 | 45.2±7.4 | <0.001 |
| Race (n, %) | 0.313 | |||||
| Caucasian | 16 (94%) | 24 (86%) | 30 (100%) | 15 (94%) | 12 (92%) | |
| Other | 1 (6%) | 4 (14%) | 0 | 1 (6%) | 1 (8%) | |
| Education | 0.214 | |||||
| Graduate | 4 (23.5%) | 6 (21%) | 3 (10%) | 1 (6%) | 1 (8%) | |
| College | 3 (17.5%) | 10 (36%) | 18 (60%) | 10 (63%) | 5 (38%) | |
| High School/GED | 9 (53%) | 9 (32%) | 8 (27%) | 4 (25%) | 6 (46%) | |
| No high School | 0 | 1 (4%) | 0 | 0 | 0 | |
| Unknown | 1 (6%) | 2 (7%) | 1 (3%) | 1 (6%) | 1 (8%) | |
| Menopausal status | 0.070 | |||||
| Premenopausal | 5 (29%) | 1 (4%) | 2 (7%) | 3 (19%) | 3 (23%) | |
| Postmenopausal | 12 (71%) | 27 (96%) | 28 (93%) | 13 (81%) | 10 (77%) | |
| Time from diagnosis (months) (mean, SD) | 21.1±8.0 | 18.0±9.3 | 24.9±9.9 | 16.3±7.0 | 20.0±9.8 | 0.015 |
| Cancer stage | 0.462 | |||||
| Stage 0 | 2 (12%) | 1 (4%) | 1 (3%) | 0 | 1 (8%) | |
| Stage 1 | 7 (41%) | 14 (50%) | 11 (37%) | 9 (56%) | 3 (23%) | |
| Stage 2 | 3 (17.5%) | 11 (39%) | 15 (50%) | 4 (25%) | 6 (46%) | |
| Stage 3 | 3 (17.5%) | 2 (7%) | 3 (10%) | 2 (13%) | 3 (23%) | |
| Unknown | 2 (12%) | 1 (6%) | ||||
| KPS (mean, SD) | 92.4±4.4 | 93.6±5.6 | 91.3±5.7 | 89.4±6.8 | 85.4±9.7 | 0.003 |
| Exercise (n, %) | 7 (41%) | 10 (36%) | 7 (21%) | 3 (19%) | 2 (15%) | 0.257 |
| Current Hormonal Therapy (n, %) | 12 (71%) | 24 (86%) | 20 (67%) | 13 (81%) | 11 (85%) | 0.593 |
| Previous Hormone Therapy (n, %) | 0 | 7 (25%) | 5 (17%) | 4 (25%) | 1 (8%) | 0.158 |
| Chemotherapy (n, %) | 7 (41%) | 12 (43%) | 15 (50%) | 8 (50%) | 8 (61%) | 0.766 |
| Radiation (n, %) | 14 (82%) | 18 (64%) | 19 (63.3%) | 13 (81%) | 9 (69%) | 0.379 |
| Surgery (n, %) | 16 (94%) | 25 (89%) | 28 (93.3%) | 15 (94%) | 11 (84%) | 0.704 |
| ER status (positive) | 14 (82%) | 24 (86%) | 26 (87%) | 12 (75%) | 12 (92%) | 0.751 |
| PR status (positive) | 11 (65%) | 23 (82%) | 21 (70%) | 11 (69%) | 10 (77%) | 0.705 |
| HER2 status (positive) | 4 (23.5%) | 4 (14%) | 6 (20%) | 2 (12.5%) | 3 (23%) | 0.773 |
SD, standard deviation; KPS, Karnofsky Performance Status; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
P-value was based on ANOVA for continuous variables and Chi-square for all categorical variables.